The US Food and Drug Administration has revoked authorizations for the use of monoclonal antibodies bamlanivimab and etesevimab (administered together) and casirivimab and imdevimab in the treatment of COVID-19.
FDA experts have determined that these drugs are very unlikely to be activ...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
